Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 2
1967 2
1969 2
1970 1
1971 1
1972 1
1973 2
1974 9
1975 5
1976 1
1977 2
1978 2
1979 1
1982 1
1985 1
1990 1
1991 1
1993 1
1995 1
1996 3
1997 8
1998 2
1999 2
2000 3
2001 4
2002 5
2003 4
2004 4
2005 1
2006 1
2007 1
2008 5
2009 4
2010 6
2011 8
2012 8
2013 8
2014 5
2015 7
2016 3
2017 6
2018 4
2019 8
2020 6
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

145 results
Results by year
Filters applied: . Clear all
Page 1
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW. de Weers M, et al. Among authors: valerius t. J Immunol. 2011 Feb 1;186(3):1840-8. doi: 10.4049/jimmunol.1003032. Epub 2010 Dec 27. J Immunol. 2011. PMID: 21187443 Free article. Clinical Trial.
FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils.
Treffers LW, van Houdt M, Bruggeman CW, Heineke MH, Zhao XW, van der Heijden J, Nagelkerke SQ, Verkuijlen PJJH, Geissler J, Lissenberg-Thunnissen S, Valerius T, Peipp M, Franke K, van Bruggen R, Kuijpers TW, van Egmond M, Vidarsson G, Matlung HL, van den Berg TK. Treffers LW, et al. Among authors: valerius t. Front Immunol. 2019 Jan 30;9:3124. doi: 10.3389/fimmu.2018.03124. eCollection 2018. Front Immunol. 2019. PMID: 30761158 Free PMC article.
IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
Treffers LW, Ten Broeke T, Rösner T, Jansen JHM, van Houdt M, Kahle S, Schornagel K, Verkuijlen PJJH, Prins JM, Franke K, Kuijpers TW, van den Berg TK, Valerius T, Leusen JHW, Matlung HL. Treffers LW, et al. Among authors: valerius t. Cancer Immunol Res. 2020 Jan;8(1):120-130. doi: 10.1158/2326-6066.CIR-19-0144. Epub 2019 Nov 5. Cancer Immunol Res. 2020. PMID: 31690649 Free article.
Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia.
Vogiatzi F, Winterberg D, Lenk L, Buchmann S, Cario G, Schrappe M, Peipp M, Richter-Pechanska P, Kulozik AE, Lentes J, Bergmann AK, Valerius T, Frielitz FS, Kellner C, Schewe DM. Vogiatzi F, et al. Among authors: valerius t. Blood. 2019 Aug 22;134(8):713-716. doi: 10.1182/blood.2019000904. Epub 2019 Jul 16. Blood. 2019. PMID: 31311816 Free article. No abstract available.
Retraction for Lammerts van Bueren et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility.
Lammerts van Bueren JJ, Bleeker WK, Brännström A, Jansson M, Peipp M, Schneider-Merck T, Valerius T, van de Winkel JG, Parren PW. Lammerts van Bueren JJ, et al. Among authors: valerius t. Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5548. doi: 10.1073/pnas.1203736109. Epub 2012 Mar 19. Proc Natl Acad Sci U S A. 2012. PMID: 22431606 Free PMC article. No abstract available.
Antibody Isotypes for Tumor Immunotherapy.
Kretschmer A, Schwanbeck R, Valerius T, Rösner T. Kretschmer A, et al. Among authors: valerius t. Transfus Med Hemother. 2017 Sep;44(5):320-326. doi: 10.1159/000479240. Epub 2017 Sep 7. Transfus Med Hemother. 2017. PMID: 29070977 Free PMC article. Review.
Myeloid immune-checkpoint inhibition enters the clinical stage.
van den Berg TK, Valerius T. van den Berg TK, et al. Among authors: valerius t. Nat Rev Clin Oncol. 2019 May;16(5):275-276. doi: 10.1038/s41571-018-0155-3. Nat Rev Clin Oncol. 2019. PMID: 30573788 No abstract available.
145 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page